JP2022531184A5 - - Google Patents

Info

Publication number
JP2022531184A5
JP2022531184A5 JP2021564270A JP2021564270A JP2022531184A5 JP 2022531184 A5 JP2022531184 A5 JP 2022531184A5 JP 2021564270 A JP2021564270 A JP 2021564270A JP 2021564270 A JP2021564270 A JP 2021564270A JP 2022531184 A5 JP2022531184 A5 JP 2022531184A5
Authority
JP
Japan
Application number
JP2021564270A
Other languages
Japanese (ja)
Other versions
JPWO2020223698A5 (https=
JP2022531184A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031169 external-priority patent/WO2020223698A1/en
Publication of JP2022531184A publication Critical patent/JP2022531184A/ja
Publication of JP2022531184A5 publication Critical patent/JP2022531184A5/ja
Publication of JPWO2020223698A5 publication Critical patent/JPWO2020223698A5/ja
Priority to JP2024114666A priority Critical patent/JP2024151337A/ja
Pending legal-status Critical Current

Links

JP2021564270A 2019-05-02 2020-05-01 がんの処置 Pending JP2022531184A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024114666A JP2024151337A (ja) 2019-05-02 2024-07-18 がんの処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842068P 2019-05-02 2019-05-02
US62/842,068 2019-05-02
PCT/US2020/031169 WO2020223698A1 (en) 2019-05-02 2020-05-01 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024114666A Division JP2024151337A (ja) 2019-05-02 2024-07-18 がんの処置

Publications (3)

Publication Number Publication Date
JP2022531184A JP2022531184A (ja) 2022-07-06
JP2022531184A5 true JP2022531184A5 (https=) 2023-05-11
JPWO2020223698A5 JPWO2020223698A5 (https=) 2023-05-11

Family

ID=73029386

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564270A Pending JP2022531184A (ja) 2019-05-02 2020-05-01 がんの処置
JP2024114666A Pending JP2024151337A (ja) 2019-05-02 2024-07-18 がんの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024114666A Pending JP2024151337A (ja) 2019-05-02 2024-07-18 がんの処置

Country Status (10)

Country Link
US (1) US20220218822A1 (https=)
EP (1) EP3962524A4 (https=)
JP (2) JP2022531184A (https=)
KR (1) KR20220004077A (https=)
CN (1) CN113766929A (https=)
AU (1) AU2020266676A1 (https=)
BR (1) BR112021021699A8 (https=)
CA (1) CA3132653A1 (https=)
IL (1) IL287652A (https=)
WO (1) WO2020223698A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230041032A (ko) * 2020-07-17 2023-03-23 서지 테라퓨틱스, 인크. 중합체 복합 제제를 포함하는 제제 및 조성물
AU2021329884A1 (en) * 2020-08-17 2023-02-16 SURGE Therapeutics, Inc. Immune modulation of myeloid derived suppressive cell function for cancer treatment
AU2022212114A1 (en) * 2021-01-30 2023-06-22 SURGE Therapeutics, Inc. Cancer therapy
KR102906748B1 (ko) * 2023-05-09 2025-12-31 국립부경대학교 산학협력단 아임계 수 가수분해를 이용한 갑각류 유래 올리고키토산의 제조방법, 이를 이용하여 제조된 올리고키토산 및 올리고키토산을 포함하는 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965379A (en) * 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
EP0820305A2 (en) 1995-04-04 1998-01-28 Wound Healing of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US6756363B1 (en) 2000-11-17 2004-06-29 Wound Healing Of Oklahoma, Inc. Solutions and films of glycated chitosan
AU2003243608A1 (en) * 2002-06-20 2004-01-06 Royer Biomedical, Inc. Resorbable delivery systems for the treatment of cancer
RU2288730C2 (ru) * 2005-02-22 2006-12-10 Научно-исследовательский институт Эпидемиологии и микробиологии Сибирского отделения Российской академии наук (НИИ ЭМ СО РАМН) Способ лечения онкогинекологических больных и гель для его осуществления
EP1942950A2 (en) * 2005-11-01 2008-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
EP3831393A1 (en) 2012-01-20 2021-06-09 Immunophotonics, Inc. Chitosan-derived compositions
US11111316B2 (en) 2012-01-20 2021-09-07 Immunophotonics, Inc. Chitosan-derived compositions
US20160008399A1 (en) * 2013-01-14 2016-01-14 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
AU2017255833B2 (en) * 2016-04-25 2022-09-01 Mizhou Hui Application of small-molecule hyaluronic acid fragment
FI3922279T3 (fi) 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)